Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domestic sugammadex vs Bridion for reversal of deep rocuronium-induced neuromuscular block in Chinese adults
ChiCTR2300071764Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Time from start of sugammadex administration to recovery of TOF ratio (TOFr) to 0.9. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on ChiCTR2300071764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071764.